What Actuaries Know About Marketing That Most Healthcare Companies Don't

How a risk-management mindset builds growth engines that convert, compound, and attract investment.

There is a conversation I have with almost every healthcare company founder at some point. It usually starts with something like: "We just need more leads. If we could get in front of more people, we'd close more deals."

It is an understandable instinct. You have a product that works. You have clinical rationale, early data, maybe a handful of pilots with genuinely encouraging results. So the logic follows: what you need is a bigger top of funnel - more outreach, more visibility, more marketing spend.

And so the marketing agency gets briefed. The LinkedIn campaigns start running. The cold email sequences get loaded. Six months later, there are more leads in the CRM... but conversion rates are no better, deal cycles are no shorter, and the CEO is still closing every deal personally.

This is the growth trap. And in healthcare, it is particularly expensive to fall into.

Before working in healthcare marketing, I spent years in the actuarial practice at PwC - a discipline built entirely around identifying, quantifying, and systematically reducing risk. Actuaries do not think about uncertainty as something to be avoided; they think about it as something to be understood, structured around, and priced.

So when I look at a company's commercial model, I do not see a lead generation issue. I see a risk architecture problem: where is the uncertainty that is preventing this from converting, scaling, or being taken seriously by the market? The framework I have developed has six components. Each targets a specific source of risk.

Why lead generation alone won't save you

The buying environment in healthcare is conservative, multi-stakeholder, and deeply risk-averse. Purchasing decisions involve clinical leads, operational managers, finance teams, procurement, and sometimes legal and information governance - each capable of stalling a deal that has otherwise progressed well. The threshold for "enough evidence" rises sharply as deal size increases. What gets you a £5k pilot does not get you a £500k multi-site rollout.

At the same time, digital advertising costs are rising and data privacy regulations are tightening targeting. The economics of pure volume-based demand generation (the "spray and pray" model) are becoming increasingly unfavourable. Customer Acquisition Cost (CAC) has become a strategic constraint on a start-up's entire growth model.

Plugging more leads into an underdeveloped conversion system does not produce more revenue; it produces more activity, more frustration, and a steadily rising cost per closed deal. The companies that scale sustainably stop asking "how do we get more leads?" and start asking "how do we build a growth engine that compounds?"

How to build a real growth engine

1. Positioning and proof: removing ambiguity at the foundation

Before a single outreach email is sent, you need to be clear on two things: who you are solving a problem for, and what evidence you have that you actually solve it. Most companies think they have this covered. In practice, many are selling to everyone and proving nothing in the language buyers actually respond to.

Positioning means making deliberate choices about which one or two segments you can win in. Proof means translating your clinical rationale and pilot data into the language of the people who hold the budget - not sensitivity statistics, but reduced hospitalisation risk, identified early, at a cost that justifies the programme. It is the ROI logic that answers the question behind almost every delayed sign-off: "Can I defend this decision?"

2. Conversion infrastructure: making it safe to say yes

In B2B healthcare, deals rarely stall because the buyer was not interested. They stall because somewhere in the process, something became too difficult to evaluate, too uncertain to implement, or too hard to justify to a committee.

Conversion infrastructure is the structured system you build to reduce that friction: clear, documented sales stages with defined entry and exit criteria; objection-handling playbooks built on real buyer objections; pilot designs structured to answer the questions a buying committee needs answered; and expansion pathways that make it clear how a £50k pilot becomes a £500k multi-site programme. A structured qualification framework such as BANT+ ensures sales effort is concentrated on accounts with genuine readiness to buy.

3. Targeted outreach: concentrating effort where it converts

Once positioning, proof and conversion architecture are in place, outreach becomes a different exercise. Rather than maximising lead volume, effective outreach is built around a defined universe of high-fit named accounts, tiered by deal size, strategic fit, and buying readiness - the logic of account-based marketing. You plan outreach backwards from your revenue target, and every touchpoint is structured around the buyer's specific problem, the evidence that addresses it, and what implementation looks like.

4. Partner credibility: borrowing the trust you haven't yet earned

In healthcare, peer endorsement and opinion-leader validation carry disproportionate weight. Buyers look for external signals that de-risk their choice, and those signals carry far more weight from a trusted peer than from the vendor. A deliberate partner credibility strategy builds those signals systematically: identify two or three high-leverage partner types whose endorsement carries weight, and design partnership activity around shared learning and evidence - co-branded case studies, joint webinars, advisory board participation - not logo placement.

5. Thought leadership: shaping the conversation before it starts

Thought leadership is probably the most misunderstood component of a digital health marketing strategy. It is frequently treated as a content volume exercise. That is not what it is for. Most decision-makers have already formed a view of the problem space long before they enter a formal procurement process. Thought leadership is how you shape that view before they get there - fewer, higher-quality assets: white papers that educate rather than promote, articles that address the specific objections that stall purchasing decisions. The goal is not reach. It is relevance.

6. Customer evidence and the feedback loop: the engine that gets smarter

Every conversation, demo, pilot, and deal won or lost is a source of intelligence. What objections came up and at which stage? What made the difference in the deals that converted? A formal feedback loop captures this systematically and feeds it back into positioning, proof assets, objection-handling, and outreach messaging. The result is a system that reduces uncertainty with every iteration - where the unknowns that slowed deal three are already answered before deal ten begins.

This is not just a revenue story

Every component above is also an asset in the eyes of a strategic buyer, investor, or partner. They are not just asking "Is revenue growing?" They are asking "Is this growth engine something we can scale? Is this market position defensible? Does this team know how to win repeatedly, or have they just landed a few founder-led deals?"

A defined ICP with a validated proof set demonstrates a repeatable value story. A structured conversion system demonstrates that commercial performance is not CEO-dependent. A partner ecosystem demonstrates distribution reach. A documented evidence base demonstrates that real-world outcomes hold up to scrutiny. These are the elements that shift a company from an interesting early-stage opportunity to a credible, de-risked investment or acquisition target.